y******1
发帖数: 730 | | y******1
发帖数: 730 | 2 Financial position:
Celsion ended December 31, 2014, with total cash and investments of $37.1
million. Management project that the current cash is enough to support
operating activities for the next two years.
Cash flows/expenses:
In 2014, Celsion used $21.4 million for operations, or approximately $1.8
million per month. Broken down, research and development costs increased to
$15 million versus $9.4 million in 2013, mainly due to initiation of the
OPTIMA study. General and administrative expenses grew to $8.9 million
compared to $6.5 million in 2013. For 2015, Celsion expects cash usage to be
around $2 million per month, which is reasonable given the increasing
enrollment in the OPTIMA study and further clinical development of the EGEN
assets. | y******1
发帖数: 730 | 3 Thinly-traded nano cap Celsion (NASDAQ:CLSN) jumps 32% premarket on
robust volume in response to its announcement of positive interim results
from a Phase 2 study assessing ThermoDox in combination with mild
hyperthermia in patients with recurrent chest wall breast cancer, a type of
cancer highly resistant to treatment.
Out of the 16 enrolled patients, 12 were eligible for evaluation for
efficacy. Eight (67%) experienced a clinical benefit while seven (58%)
showed a local response, including five complete responses, two partial
responses and one with stable disease.
Enrollment should be completed in Q3.
ThermoDox is encapsulated doxorubicin. After infusion, it is heated to a
specific temperature which releases the cancer drug directly into a tumor. |
|
